Literature DB >> 26411348

Total glycosides of Yupingfeng protects against bleomycin-induced pulmonary fibrosis in rats associated with reduced high mobility group box 1 activation and epithelial-mesenchymal transition.

Wenhui Cui1,2, Liucheng Li3, Delin Li4, Xiaoting Mo1,2, Wencheng Zhou1,2, Zhihui Zhang2, Liang Xu4, Ping Zhao4, Lianwen Qi5, Ping Li5, Jian Gao6,7.   

Abstract

BACKGROUND: Pulmonary fibrosis (PF) is a fatal inflammatory disease with limited effective strategies. Epithelial-mesenchymal transition (EMT) is a pivotal origin of myofibroblasts that secrete extracellular matrix (ECM) in the development of PF. High mobility group box 1 (HMGB1), one of the mediators of inflammation, has been proved abnormal activation in the pathogenesis of PF. AIM: The present study was aimed to investigate the potential effects of total glycoside of Yupingfeng (YPF-G), the natural compound extracted from Yupingfeng san, on HMGB1 activation and EMT in bleomycin-induced PF, which was a serious disease of respiratory system.
METHODS: The Sprague-Dawley (SD) rat model of PF was duplicated by intratracheal instillation of bleomycin (5 mg kg(-1)). After that, YPF-G (5, 10 mg kg(-1)) and prednisone (5 mg kg(-1)) were separately administered intragastrically, and then the rats were killed at days 14 and 28, respectively. Hematoxylin and eosin and Masson's trichrome staining were performed to assess the histopathologic level of lung tissues, western blotting and the common kits were utilized to investigate the hallmarks molecule expression of ECM and EMT, and the level of HMGB1 in lung tissues and serum.
RESULTS: We found that both dose of YPF-G markedly reduced bleomycin-induced alveolitis and PF in rats. Besides, the levels of HMGB1, laminin, hyaluronic acid, and hydroxyproline were effectively reduced. Meanwhile, the increased protein expression of HMGB1 and the mesenchymal markers including vimentin and alpha-smooth muscle actin, and the decreased protein expression of epithelial marker E-cadherin were dramatically inhibited after YPF-G treatment.
CONCLUSION: Our results demonstrated that YPF-G could ameliorate bleomycin-induced PF by reducing HMGB1 activation and reversing EMT.

Entities:  

Keywords:  Epithelial–mesenchymal transition; High mobility group box 1; Pulmonary fibrosis; Total glycosides of Yupingfeng

Mesh:

Substances:

Year:  2015        PMID: 26411348     DOI: 10.1007/s00011-015-0878-x

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  31 in total

Review 1.  Fibronectin at a glance.

Authors:  Roumen Pankov; Kenneth M Yamada
Journal:  J Cell Sci       Date:  2002-10-15       Impact factor: 5.285

Review 2.  Idiopathic pulmonary fibrosis: from epithelial injury to biomarkers--insights from the bench side.

Authors:  Keren Borensztajn; Bruno Crestani; Martin Kolb
Journal:  Respiration       Date:  2013-12-14       Impact factor: 3.580

3.  Antifibrosis effects of total glucosides of Danggui-Buxue-Tang in a rat model of bleomycin-induced pulmonary fibrosis.

Authors:  Jian Gao; Yan Huang; Ping Li; Dujuan Xu; Jun Li; Yong Liu; Zhaogang Huang; Qiang Wu; Xu Shao
Journal:  J Ethnopharmacol       Date:  2011-03-21       Impact factor: 4.360

Review 4.  HMGB1 as a potential therapeutic target for neuropathic pain.

Authors:  Takehiko Maeda; Masanobu Ozaki; Yuka Kobayashi; Norikazu Kiguchi; Shiroh Kishioka
Journal:  J Pharmacol Sci       Date:  2013-11-26       Impact factor: 3.337

5.  The role of the receptor for advanced glycation end-products in lung fibrosis.

Authors:  Mei He; Hiroshi Kubo; Kota Ishizawa; Ahmed E Hegab; Yasuhiko Yamamoto; Hiroshi Yamamoto; Mutsuo Yamaya
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2007-10-19       Impact factor: 5.464

6.  Antiinflammatory and immunoregulatory effects of total glucosides of Yupingfeng powder.

Authors:  Jian Gao; Jun Li; Xu Shao; Yong Jin; Xiong-wen Lü; Jin-fang Ge; Yan Huang; Lei Zhang; Lin Chen
Journal:  Chin Med J (Engl)       Date:  2009-07-20       Impact factor: 2.628

7.  The role of high mobility group box1 in pulmonary fibrosis.

Authors:  Naoki Hamada; Takashige Maeyama; Tomonobu Kawaguchi; Michihiro Yoshimi; Jyutaro Fukumoto; Mizuho Yamada; Singo Yamada; Kazuyoshi Kuwano; Yoichi Nakanishi
Journal:  Am J Respir Cell Mol Biol       Date:  2008-04-25       Impact factor: 6.914

8.  Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis.

Authors:  T J Broekelmann; A H Limper; T V Colby; J A McDonald
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

9.  Anti-inflammatory and immunoregulatory effects of Yupingfeng powder on chronic bronchitis rats.

Authors:  Jue Song; Jun Li; Shi-Rui Zheng; Yong Jin; Yan Huang
Journal:  Chin J Integr Med       Date:  2013-03-15       Impact factor: 1.978

10.  Melatonin inhibits endoplasmic reticulum stress and epithelial-mesenchymal transition during bleomycin-induced pulmonary fibrosis in mice.

Authors:  Hui Zhao; Qing-Qing Wu; Lin-Feng Cao; Hou-Ying Qing; Cheng Zhang; Yuan-Hua Chen; Hua Wang; R Y L Liu; Rong-Ru Liu; De-Xiang Xu
Journal:  PLoS One       Date:  2014-05-12       Impact factor: 3.240

View more
  8 in total

1.  Astragaloside IV Improves Bleomycin-Induced Pulmonary Fibrosis in Rats by Attenuating Extracellular Matrix Deposition.

Authors:  Liu-Cheng Li; Liang Xu; Yan Hu; Wen-Jie Cui; Wen-Hui Cui; Wen-Cheng Zhou; Lian-Di Kan
Journal:  Front Pharmacol       Date:  2017-08-08       Impact factor: 5.810

2.  A network pharmacology-based approach to analyse potential targets of traditional herbal formulas: An example of Yu Ping Feng decoction.

Authors:  Huali Zuo; Qianru Zhang; Shibing Su; Qilong Chen; Fengqing Yang; Yuanjia Hu
Journal:  Sci Rep       Date:  2018-07-30       Impact factor: 4.379

3.  Nrf2 attenuates inflammatory response in COPD/emphysema: Crosstalk with Wnt3a/β-catenin and AMPK pathways.

Authors:  Wenhui Cui; Zhihui Zhang; Panpan Zhang; Jiao Qu; Cheng Zheng; Xiaoting Mo; Wencheng Zhou; Liang Xu; Hongwei Yao; Jian Gao
Journal:  J Cell Mol Med       Date:  2018-04-16       Impact factor: 5.310

Review 4.  Traditional Chinese medicine for pulmonary fibrosis therapy: Progress and future prospects.

Authors:  Liu-Cheng Li; Lian-Di Kan
Journal:  J Ethnopharmacol       Date:  2016-12-28       Impact factor: 4.360

Review 5.  A systematic review of outcomes in COVID-19 patients treated with western medicine in combination with traditional Chinese medicine versus western medicine alone.

Authors:  Ruizhe Yu; Shihan Zhang; Dejian Zhao; Zhanpeng Yuan
Journal:  Expert Rev Mol Med       Date:  2022-01-06       Impact factor: 5.600

6.  The Protective Effect of Naringin against Bleomycin-Induced Pulmonary Fibrosis in Wistar Rats.

Authors:  Nergiz H Turgut; Haki Kara; Sahende Elagoz; Koksal Deveci; Huseyin Gungor; Emre Arslanbas
Journal:  Pulm Med       Date:  2016-02-10

Review 7.  Drugs and Targets in Fibrosis.

Authors:  Xiaoyi Li; Lixin Zhu; Beibei Wang; Meifei Yuan; Ruixin Zhu
Journal:  Front Pharmacol       Date:  2017-11-23       Impact factor: 5.810

8.  Jiedu Sangen Decoction Inhibits Migration and Invasion of Colon Cancer SW480 Cells via Suppressing Epithelial Mesenchymal Transition.

Authors:  Kai Zhang; Tao Peng; Qingying Yan; Leitao Sun; Haojun Miao; Li Yuan; Yuxin Hong; Mengmeng Zhou; Kaibo Guo; Leyin Zhang; Jing Fang; Minhe Shen; Shanming Ruan
Journal:  Evid Based Complement Alternat Med       Date:  2018-09-25       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.